Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

American Journal of Hematology

Volumn 89, Issue 5, 2014, Pages 509-516

  Daver, Naval ^a   Naqvi, Kiran ^b   Jabbour, Elias ^a   Kadia, Tapan ^a   Dinardo, Courtney ^a   Cardenas Turanzas, Marylou ^a   Pierce, Sherry ^a   Nguyen, Khanh Thi Thuy ^a   Bueso Ramos, Carlos ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ADULT COMORBIDITY EVALUATION 27; AGED; ARTICLE; CANCER CENTER; CANCER PROGNOSIS; COMORBIDITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898445859     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23675     Document Type: Article

References (39)

1. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:692-701.
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
6. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538-543.
7. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
8. Santos FP, Kantarjian H, Garcia-Manero G, et al. The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep 2011;6:13-21.
9. Hugo SE, Bundrick SC, Hanson CA, et al. Independent validation of the MD Anderson Cancer Center risk model for myelodysplastic syndromes (MDS), and comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization-based prognostic scoring system (WPSS). Blood 2009;114:1467-1468.
10. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007;110:4385-4395.
11. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
12. Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes: Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2013;11:838-874.
13. Valcarcel D, Montesinos P, Sanchez-Ortega I, et al. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer 2012;118:410-417.
14. Messa E, Gioia D, Evangelista A, et al. High predictive value of the revised international prognostic scoring system (IPSS-R): An external analysis of 646 patients from a multiregional Italian MDS Registry. Blood 2012;120, ASH meeting abstract 1702.
15. Mishra A, Al Ali NH, Corrales-Yepez M, et al. Validation of the revised international prognostic scoring system (R-IPSS) for patients with myelodysplastic syndromes: Therapeutic implications. Blood 2012;120, ASH meeting abstract 2816.
16. Cermak J, Mikulenkova D, Brezinova J, et al. A reclassification of Myelodysplastic Syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall survival. A retrospective analysis of 49 patients. Blood 2012;120, ASH meeting abstract 4957.
17. Piccirillo JF, Costas I. The impact of comorbidity on outcomes. ORL J Otorhinolaryngol Relat Spec 2004;66:180-185.
18. Feinstein A. Pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis 1970;23:455-468.
19. Albertsen PC, Fryback DG, Storer BE, et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127-132.
20. Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
21. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593-602.
22. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 1998;82:2123-2134.
23. Wells CK, Stoller JK, Feinstein AR, et al. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med 1984;144:2004-2009.
24. Miller DC, Taub DA, Dunn RL, et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003;169:105-109.
25. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-2447.
26. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model. J Clin Oncol 2011;29:2240-2246.
27. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chron Dis 1974;27:387-404.
28. Piccirillo JF, Costas I, Claybour P, et al. The measurement of comorbidity by cancer registries. J Registry Manage 2003;30:8-14.
29. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-829.
30. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384-1395.
31. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616-3627.
32. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
33. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119:3578-3584.
34. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
35. Larsson CA, Cote G, Quintas-Cardama A. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11:815-827.
36. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012;26:1730-1741.
37. Wang R, Gross CP, Halene S, et al. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009;33:1594-1598.
38. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica 2009;94:602-606.
39. Pfeilstocker M, Karlic H, Nosslinger T, et al. Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. Leuk Lymphoma 2007;48:1900-1909.